Washington University School of Medicine announced on Friday a new clinical trial to investigate three anti-inflammatory drugs in patients with COVID-19. The trial, which is funded by the National Institutes of Health, aims to enroll 2,000 patients hospitalized with moderate to severe COVID-19, and is expected to last six months.